Oncolytics Biotech Posts $28.76M Annual Loss, Zero Revenue in Latest 10-K
ONCY has more than doubled off its 52-week low of $0.326.
Summary
Oncolytics Biotech reported its annual financial results for the year ended December 31, 2025, via its 10-K filing, disclosing $0 in revenue, a net loss of $28.76 million, and an EPS of $(0.30). This filing provides the full annual financial picture for the company, following recent positive clinical data announcements and a corporate redomestication. For a clinical-stage biotech company, zero revenue and a net loss are expected as it focuses on drug development, meaning these figures are generally in line with expectations. The article also highlights positive business developments, including progress in clinical programs, Fast Track designation, and plans for an FDA meeting for a registrational study. Investors will continue to monitor the company's cash burn rate, progress in its clinical trials, and upcoming regulatory milestones, particularly the planned FDA meeting and preliminary data from the Phase 2 mCRC study expected by year-end.
At the time of this announcement, ONCY was trading at $0.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $86.6M. The 52-week trading range was $0.33 to $1.51. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.